Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo... 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
FDA approves AstraZeneca's Imfinzi with chemotherapy for early-stage lung cancer, based on pivotal AEGEAN trial. Imfinzi shows significant event-free survival and pathologic complete response benefits.... 
Via Benzinga
Exposures Product Safety
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
From AstraZeneca
Via Business Wire
Is NASDAQ:AZN a Suitable Choice for Quality Investing?
Why Quality-Oriented Investors Should Consider NASDAQ:AZN. 
Via Chartmill
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
From AstraZeneca
Via Business Wire
AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding
AstraZeneca is raising concerns that a manufacturing site could be relocated to France, putting an investment in jeopardy. 
Via Benzinga
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
AstraZeneca, T-Mobile US, and Intuitive Surgical are hitting all-time highs, driven by solid sector performance, robust earnings, and strategic advancements. 
Via MarketBeat
Topics ETFs
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth. 
Via InvestorPlace
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
Via Benzinga
Exposures COVID-19
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical... 
Via Benzinga
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit... 
Via Benzinga
Top Analyst Reports For AstraZeneca, TotalEnergies & ConocoPhillips
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC, TotalEnergies SE and ConocoPhillips. 
Via Talk Markets
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
The winners of today might not compete in the lucrative new segment of tomorrow. 
Via The Motley Fool
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2%
The Bank of England cuts interest rate for first time in over 4 years to 5%, citing inflation below target and emerging economic slack. Pound falls, UK stocks hold steady. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
AstraZeneca CEO Pascal Soriot urges the UK government to reassess drug funding after NICE deems Enhertu too costly, highlighting concerns over new methodology affecting advanced cancer treatments and... 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks arguably deserve more respect from investors. 
Via The Motley Fool
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu. 
Via MarketBeat
Topics ETFs
7 Explosive Growth Stocks Set to Soar in 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024. 
Via InvestorPlace
Why AstraZeneca Stock Is Sliding Today
The British drugmaker's Q2 results were good, but seemingly not good enough for many investors. 
Via The Motley Fool
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
AZN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. 
Via Benzinga
Topics Economy
Exposures Economy
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook
The company no longer expects its earnings to decline this year. Instead, AstraZeneca called for stable profit. 
Via Investor's Business Daily
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
AstraZeneca's Q2 sales rose 13% to $12.94 billion, beating expectations. Oncology sales grew 15% to $5.33 billion. Notable drug performances include Tagrisso up 8%, Calquence up 21%, and Farxiga up... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.